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Abstract
Background:  New and improved antimicrobial countermeasures are urgently needed to
counteract increased resistance to existing antimicrobial treatments and to combat currently
untreatable or new emerging infectious diseases. We demonstrate that computational comparative
genomics, together with experimental screening, can identify potential generic (i.e., conserved
across multiple pathogen species) and novel virulence-associated genes that may serve as targets
for broad-spectrum countermeasures.
Results:  Using phylogenetic profiles of protein clusters from completed microbial genome
sequences, we identified seventeen protein candidates that are common to diverse human
pathogens and absent or uncommon in non-pathogens. Mutants of 13 of these candidates were
successfully generated in Yersinia pseudotuberculosis and the potential role of the proteins in
virulence was assayed in an animal model. Six candidate proteins are suggested to be involved in
the virulence of Y. pseudotuberculosis, none of which have previously been implicated in the virulence
of Y. pseudotuberculosis and three have no record of involvement in the virulence of any bacteria.
Conclusion: This work demonstrates a strategy for the identification of potential virulence factors
that are conserved across a number of human pathogenic bacterial species, confirming the
usefulness of this tool.
Background
Microbial disease is the major cause of human death and
morbidity and for many infectious diseases, no preventive
vaccines are available [1]. Where therapies do exist, esca-
lation of resistance to antimicrobials hinders treatment of
common bacterial infections and accentuates the need for
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new approaches [2,3]. Therefore, it is imperative to iden-
tify appropriate targets for medical countermeasures such
as antimicrobial drugs or cross-protective vaccines active
against several pathogenic strains or species. An alterna-
tive to "killing" bacteria, which exacerbates the selection
of antimicrobial resistance, is to "disarm" bacteria by
interfering with their capacity to be virulent, thus enabling
the bacterium to survive and evoke an appropriate
immune protection [4]. Targeting such virulence factors
through the development of antivirulence (as opposed to
antimicrobial) compounds has indicated that it is possi-
ble to target common virulence genes [5,6].
Virulence is typically described as the damage a pathogen
causes to the host during infection [7]. Gene products that
contribute to virulence can therefore be described as viru-
lence factors. Traditionally a gene has been classified to
encode a virulence factor by experimentally introducing a
mutation into the protein of interest and determining
whether virulence of the resultant mutant is reduced.
Genome-wide screens for identifying novel virulence fac-
tors have traditionally employed transposon mutagenesis
to inactivate genes in a selected bacterial strain and then
screening the resulting insertion mutants for attenuation
in an appropriate animal infection model. An adaptation
of this method has been the incorporation of unique DNA
tags in signature-tagged mutagenesis (STM) which ena-
bles mutants to be screened en masse in animal infection
models [8]. However, this approach is limited to a single
strain of a particular bacterial species and a particular
infection model. Therefore the approach typically identi-
fies highly specific virulence factors with limited extrapo-
lation to generic virulence determinants of other
pathogens. Another approach is to identify genes up-reg-
ulated in vivo, such as in vivo expression technology (IVET)
[9]. However, this approach also identifies genes other
than those required for virulence and both STM and IVET
identify genes in a pathogen that are also present in non-
pathogens.
Computational approaches to identifying virulence fac-
tors have often been made through whole-genome com-
parisons of two or more bacteria, where the presence or
absence of genes between closely related pathogenic and
non-pathogenic strains can suggest genes that potentially
play a role in virulence [10,11]. For example, Garbom et
al. [12] identified novel virulence-associated genes in Yers-
inia pseudotuberculosis by looking at the hypothetical genes
(genes of unknown function) conserved in six human
microbial pathogens. Expanding on this work, we have
used whole proteome searches to identify virulence-asso-
ciated proteins common to diverse pathogenic bacteria
that are absent in non-pathogenic species. The identified
factors can then be exploited for the development of med-
ical countermeasures such as antimicrobials, vaccines or
diagnostics.
In contrast to computational approaches based on simi-
larity, genomic context methods involve several non-sim-
ilarity based approaches to predict protein functions and
interactions [13-17]. Phylogenetic profiles particularly
suit our objective of identifying conserved virulence fac-
tors across multiple human pathogenic species. The
method was originally designed to identify functionally-
related proteins that evolve in a correlated fashion by
characterizing proteins by a binary string that encodes the
presence or absence of the protein in every known
genome [18]. The method has been improved and
expanded in numerous ways, including new approaches
to characterize profile patterns by domains [19] and pro-
tein families [20] and by integrating phylogenetic infor-
mation to compute probabilities of observing different
profile strings [21,22]. Phylogenetic profiles have been
used to identify virulence factors related to bacterial food
poisoning [23] and intracellular pathogenesis [24]. In this
work, we have utilized a similar approach to identify
potential virulence factors present in a group of extreme
human pathogens, bacteria from the Centers for Disease
Control category A and B pathogen lists (http://
www.bt.cdc.gov/agent/agentlist-category.asp). We
impose two primary criteria: first, the putative target genes
must be broadly present in the diverse pathogens within
these two groups. Second, the putative target genes should
be absent or highly divergent in non-pathogens. This
enhances the likelihood that candidates are implicated in
virulence and minimizes the potential activity of future
countermeasures against the host commensal flora.
Results
Clustering of proteins
Our targets of interest are proteins that are present in
diverse pathogens but absent from non-pathogens, and
therefore we had to decide which proteins in different
organisms should be treated as the same protein. We
began by doing an all against all BLAST comparison of a
collection of 617,000 proteins from all 214 completely
sequenced microbial genomes available at the time. The
resulting 123 million BLAST hits were grouped into clus-
ters using single-linkage clustering at eight different per-
cent identity and query coverage cut-offs. Finally,
phylogenetic profile tables were created to summarize the
presence or absence of proteins within a cluster across all
genomes.
Searching for virulence-associated proteins
We searched for virulence-associated proteins in the phy-
logenetic profile tables using the BLAST Clusters link on
the Toxin and Virulence Factor website (TVFac) at Los Ala-
mos National Laboratory (http://www.tvfac.lanl.gov). We
assigned representative strains taken from the CDC cate-
gory A and B pathogen lists to the target group (Table 1).
Fifty-two non-pathogenic strains were included in the
background group (Additional file 1). These were selectedBMC Genomics 2009, 10:501 http://www.biomedcentral.com/1471-2164/10/501
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from the 214 genomes as having no association with
human pathogenesis, or in fact no pathogenesis in animal
and plants. Bacteria that have been identified as oppor-
tunistic pathogens were excluded from both lists as their
mode of action may be as much to do with an immuno-
compromised host as the possession of traditional viru-
lence factors by the bacteria. Next, we selected a minimum
of five hits to the category A and B pathogens and maxi-
mum of three hits to non-pathogens and identified 1024
potential generic virulence factor candidates using the
50% identity and 90% coverage cutoffs (Table 2). Other
combinations were exhaustively tested but more stringent
cutoffs resulted in too few candidates whilst less stringent
ones gave too many for our purposes.
Selecting candidates for experimental screening
Since it was impractical to experimentally test all 1024
candidates, additional down-selection was performed to
narrow the number of candidates to a more manageable
number. The final proteins used in experimental testing
were selected based on a number of different criteria. The
selected protein is required to have an ortholog in Y. pseu-
dotuberculosis since this was our experimental pathogen to
investigate virulence and 87 candidates were found to
have no Y. pseudotuberculosis homolog in the cluster. Since
it is possible that one closely-related protein could com-
pensate for the loss in function of the other [25], a further
21 clusters with multiple hits to Y. pseudotuberculosis were
also removed. Since only completely sequenced microbial
genomes were included in the database, each target pro-
tein was also compared against protein sequences from
eukaryotes and other organisms by following links on
TVFac to pre-computed BLAST results available at NCBI
(National Center for Biotechnology Information). Those
targets with an identity of 50% or more to eukaryotes,
and/or 50% or greater identity to 3 or more non-patho-
gens, were also removed from the list. By these considera-
tions the number of candidates was narrowed down to 17
potential targets for experimental testing, of which thir-
teen of these were successfully constructed as mutants
(Table 3).
The top hit from the cluster search was a superoxide dis-
mutase C (SodC) with hits to nine category A and B path-
ogens and none from the non-pathogen group. Although
several forms of this enzyme are found in both pathogenic
and non-pathogenic bacteria as well as most other organ-
isms including eukaryotes, this particular cluster included
only pathogenic bacteria. This suggests that SodC from
pathogens is distinct from non-pathogens at the amino
acid sequence level when compared at the described cut-
offs (50% identity and 90% coverage). Similarly, where
targets are given as absent in a certain bacterium, this does
not mean that no homolog can be found in that organ-
ism, but rather no homolog can be found at the cut-off
levels used for this search.
Testing virulence in Y. pseudotuberculosis
The growth rate of each mutant was compared to that of
the wild-type (Additional file 2). No statistically signifi-
cant differences between growth curves were observed (P
> 0.05, using an ANCOVA, comparing sigmoidal dose
models, fitted to the data). It is therefore unlikely that any
of the genetic mutations in this study have affected the
ability for them to grow in media. Mice were inoculated as
described with doses ranging from 1 to 104 cfu of wild
type Y. pseudotuberculosis strain IP32953 (see Methods for
complete details). The median lethal dose (MLD) via the
Table 1: Pathogen strains in profile searches
Phylum or Class Strain Abbreviation
Firmicutes Bacillus anthracis str. Ames Ancestor Ba
Alphaproteobacteria Brucella melitensis 16M Bme
Alphaproteobacteria Rickettsia prowazekii str. Madrid E Rp
Betaproteobacteria Burkholderia mallei ATCC 23344 Bma
Betaproteobacteria Burkholderia pseudomallei K96243 Bp
Gammaproteobacteria Coxiella burnetii RSA 493 Cb
Gammaproteobacteria Escherichia coli O157:H7 Ec
Gammaproteobacteria Francisella tularensis subsp. tularensis Schu 4 Ft
Gammaproteobacteria Salmonella enterica serovar Typhi Ty2 Se
Gammaproteobacteria Salmonella typhimurium LT2 St
Gammaproteobacteria Shigella flexneri 2a str. 301 Sf
Gammaproteobacteria Vibrio cholerae O1 biovar eltor str. N16961 Vc
Gammaproteobacteria Yersinia pestis CO92 Yp
Gammaproteobacteria Yersinia pseudotuberuculosis IP32953 Yptb
Strains of select agents (CDC category A and B bacteria) assigned to the target group in profile searches. Genomes sequences from some select 
agents were unavailable at the time (Clostridium botulinum and Chlamydia psittaci) and the toxin-producing strains of Staphylococcus aureus and 
Clostridium perfringens were excluded from the searches. Where multiple strains had been sequenced (such as for Bacillus anthracis and Yersinia 
pestis), a single representative strain was selected so that results were not skewed to favor species with multiple entries.BMC Genomics 2009, 10:501 http://www.biomedcentral.com/1471-2164/10/501
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i.v. route was calculated to be 2 cfu, consistent with that
previously reported [26]. Thirteen of the 17 target genes
were inactivated by allelic replacement in Y. pseudotubercu-
losis and tested for reduced competitiveness with the wild
type strain after i.v. challenge of mice. Four genes could
not be constructed despite repeated attempts. For this
study, a mutant was considered to be attenuated if it had
a competitive index (CI) value of 0.2 or less. Based on this,
six genes were identified that reduced virulence of Y. pseu-
dotuberculosis  (Table 3). None of the encoded proteins
have been previously reported to play a role in virulence
of Y. pseudotuberculosis, although three have been reported
as playing a role in the virulence of other bacteria. It is
possible however, that the genes themselves are not
directly involved in virulence but have an effect on other
genes that are.
Discussion
The lifestyles of all of the pathogens selected for this study
are known to involve survival in phagocytes and of the
genes down-selected, several are implicated in the survival
of bacteria within phagocytic cells. SodC is known to be a
virulence factor in several pathogenic bacteria including
Neisseria meningitides [27], Burkholderia cenocepacia [28],
Salmonella enterica serovar  Typhimurium  and  Salmonella
choleraesuis [29] and Brucella abortus [30], and disruption
of the sodC gene in these bacteria have generated attenu-
ated mutants. Further work has characterized the role of
superoxide dismutase C in the virulence in Y. pseudotuber-
culosis [31]. SodC is known to protect bacteria in phago-
somes from the bactericidal action of superoxide anion,
and SodC orthologs were found in most of the pathogens
targeted for this study [32]. Burkholderia mallei, Burkholde-
ria pseudomallei and Bacillus anthracis are also known to
have SodC, but these enzymes do not show significant
sequence homology with the cluster of SodC orthologs in
this study at the 50% identity and 90% coverage cut-offs
used.
Table 2: Summary of candidates from profile searches.
Non-pathogens
012 3
Pathogens 5 368 125 44 33
6 20 119 145 82
7 9 17 13 20
81 4 4 1 4
91 0 2 3
A total of 1024 potential virulence factor clusters were identified in 
the phylogenetic profile tables. At least five hits to pathogens of 
interest were required and no more than three hits to non-pathogens 
were allowed.
Table 3: Selected targets
CI YPTB Locus Definition 50-90 Cluster ID Total non-pathogens Total pathogens Pathogen strains
0.01 2410 Magnesium transport ATPase 
mgtB
1035 3 8 Bme, Bma, Bp
0.03 2913 Deoxyribopyrimidine 
photolyase phrB
2801 0 6 Vc
0.06 2705 Putative manganese transport 
protein mntH
1611 3 8 Ba, Bma, Bp
0.12 3827 Outer membrane biogenesis 
protein
2798 0 5 -
0.13 0181 Putative protohaeme IX 
biogenesis protein hemY
3642 0 5 -
0.16 0756 Superoxide dismutase C sodC 1306 0 9 Bme, Cb, Ft, Vc
0.39 1340 Lysine specific permease cadR 563 2 9 Ba, Bma, Bp, Ft
0.42 0242 Glycerophosphoryl diester 
phosphodiesterase glpQ
2411 0 7 Bma, Bp
0.45 2699 Hypothetical protein 3924 0 7 Bma, Bp
0.76 1424 Hypothetical protein 1031 3 9 Bma, Bp, Ft, Vc
0.87 3166 Thiol:disulphide interchange 
protein dscB
3283 0 5 -
2.38 0188 Frataxin-like protein cyaY 2139 2 6 Vc
3.15 3505 Stringent starvation protein sspB 1207 3 7 Cb, Vc
ND 1167 Phosphate starvation protein 3911 0 6 -
ND 1251 Ecotin 3380 0 6 -
ND 2026 MviN-like protein 1296 3 9 Bma, Bp, Cb
ND 2995 Putative surface antigen 2296 2 7 Vc
Virulence-associated genes identified by computational methods and selected for experimental screening. These targets have been ranked by their 
competitive index (CI) value in Y. pseudotuberculosis. The CI value shown is the mean of the CI calculated from 3 spleens individually plated in 
triplicate. The top six candidates are deemed virulence-related by our experimental criteria. Hits to pathogens include all five members of the 
Enterobacteriaceae (Ec, Se, Sf, St, Yp) plus the additional strains listed using abbreviations from Table 1.BMC Genomics 2009, 10:501 http://www.biomedcentral.com/1471-2164/10/501
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Both Mg2+ and Mn2+ are believed to be limiting in the
phagosome, and transport systems for these ions are com-
mon to many of the pathogens targeted for this study [33].
Bacterial MntH proteins are homologous to the eukaryo-
tic NRAMP (natural-resistance-associated macrophage
protein) family of proteins that transport either Mn2+ or
Fe2+. Mutants of the mntH  gene (manganese transport
protein) have been shown to be attenuated in Salmonella
typhimurium [34]. In S. typhimurium, the magnesium trans-
port ATPase gene, mgtB, is found on a pathogenicity
island, SPI-3, and its expression is controlled by the PhoP/
Q signal transduction system which is an essential system
in Salmonella virulence [35].
HemY is a putative protoporphyrinogen IX oxidase that is
found as part of the haem biosynthetic pathway in bacte-
ria. Haem is a tetrapyrrole derivative commonly used as a
prosthetic group in proteins such as cytochromes, cata-
lases and peroxidases and is essential for respiration and
defence against oxygen intermediates. This later function
suggests a possible involvement as a host defense mecha-
nism. Although no hemY gene has been associated with
virulence to date, Staphylococcus aureus mutants of hemB
have been shown to reduce virulence in the Caenorhabditis
elegans infection model [36].
YPTB3827 is an uncharacterized protein which contains
the COG domain COG2982, involved in outer membrane
biogenesis [Cell envelope biogenesis, outer membrane].
The outer membrane of Gram-negative bacteria is made
up of four major components: lipopolysaccharide, phos-
pholipids, beta-barrel proteins, and lipoproteins [37].
Together they play a number of roles including maintain-
ing the integrity of the cell, uptake and secretion of solutes
and interaction with the host cell. YPTB3827 has not pre-
viously been associated with virulence. However, it is pos-
sible that disruption of this protein may affect virulence
though interactions with the host cell, or through secre-
tion of certain proteins. Further work on this protein will
be required to further characterize its role and to elucidate
its role in virulence.
Of the 17 targets, four could not be constructed as
mutants suggesting that their function may be essential to
the virulence of the cell. Each of these were compared to
the Database of Essential Genes (DEG: http://
tubic.tju.edu.cn/deg) and two, YPTB2995 and YPTB2026,
showed over 50% identity to proteins described as essen-
tial in this database [38].
Conclusion
Of the 13 mutants constructed, six were identified as hav-
ing potential association with the virulence of Y. pseudotu-
berculosis (42%), suggesting that this selection process -
guided primarily by the comparative presence or absence
of potential targets in pathogens versus non-pathogens - is
a promising tool for the identification of potential viru-
lence-associated proteins. However, further work is
needed to confirm whether these targets are important to
Y. pseudotuberculosis outside the laboratory and whether
these targets are also associated with virulence in other
pathogens. Work is currently underway to characterize
each of the targets and to demonstrate their roles in viru-
lence. This work has already been completed for superox-
ide dismutase where it has been shown to be essential for
the virulence of Y. pseudotuberculosis in both insect and
mammalian hosts [31]. Similarly, to confirm the identi-
fied targets as generic, we are now carrying out studies in
a range of bacterial pathogens.
An advantage of our approach is that commensal flora,
which often play important roles in the well-being of
humans, should be minimally affected. This is dramati-
cally illustrated in the development of Clostridium difficile-
associated colitis where the administration of broad-spec-
trum antibiotics significantly impacts the commensal gut
flora producing an environment where the pathogenic C.
difficile can proliferate [39]. Additional grounds for target-
ing virulence per se is furnished by recent metagenomic
studies in humans, which suggest that the human metage-
nome contains several orders of magnitude more micro-
bial genes than Homo sapiens genes and that our bodies
themselves contain perhaps ten times as many microbial
cells as "human" ones [40,41]. Avoiding potential disrup-
tion to this vast microbial community is thus highly desir-
able as commensals are now known to contribute to gut
immunity and the synthesis of vital nutrients [39,42,43].
Since this work was started, the number of whole genome
sequences has increased greatly and new protein family
and cluster databases are readily available for searching.
The TVFac website now includes phylogenetic profile
tables created from 14 database cross-references and three
UniRef clusters in UniProt [44]. As of July 2009, over
1430 microbial and nearly 80 eukaryotic genomes are cur-
rently represented in these tables. Further studies could be
carried out with these extended datasets with the possibil-
ity of identifying more potential candidates. The success
rate we observed in spite of these limitations suggests that
improved methods along the lines suggested should fur-
ther enhance the discovery of virulence-associated pro-
teins that are conserved within a number of human
pathogenic bacteria.
Methods
Our approach in finding virulence-associated genes com-
mon to human pathogens followed three levels of compu-
tational pre-screening followed by experimental analysis
of the resulting candidates. The computational steps
reduced the number of potential targets from over 77,500BMC Genomics 2009, 10:501 http://www.biomedcentral.com/1471-2164/10/501
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to 17 candidates. The experimental screening suggests that
six of these candidates are virulence factors in Y. pseudotu-
berculosis and potential targets for countermeasures (flow-
chart in additional file 3).
Computational methods
A collection of 617,000 proteins was downloaded from
214 completely sequenced microbial genomes available
on the NCBI ftp site (ftp://ftp.ncbi.nih.gov/genomes/Bac
teria) in February 2005. The entire set of proteins was
blasted all against all using BLASTP 2.2.10 on a 240-node
Linux cluster. Soft-masking was used to avoid initial
matches based on low complexity sequences and to allow
extensions through masked regions. For each query pro-
tein, the top 1000 subject proteins with an e-value below
10-5 were retained producing a final tab-delimited blast
output file with almost 123 million rows of data. The pro-
teins were grouped into clusters at eight different percent
identity and query coverage cutoffs using a custom-built
single-linkage clustering program written in C++. The
clustering results were loaded into a MySQL database and
cross-tabulations were run to create profile tables summa-
rizing the presence or absence of proteins across all
genomes. For example, 418,000 proteins were grouped
into 77,500 clusters ranging in size from 2 to 506 proteins
using 50% identity and 90% query coverage cut-offs. The
corresponding profile table therefore contains 77,500
rows for each cluster and 214 columns, one for each
genome.
The profiles tables were searched using the BLAST Clusters
link on Toxin and Virulence Factor website (http://
www.tvfac.lanl.gov). In order to facilitate comparisons
among groups of organisms in the profile tables, we first
collected detailed information on host-pathogen interac-
tions including the source of infection, methods of trans-
mission and the ability of the pathogen to cause infection.
The organism-based annotations were then linked to the
search page to allow users to quickly highlight and select
a target and background group. We selected "CDC patho-
gens -species" to highlight one representative strain of cat-
egory A and B pathogens and moved those 13 taxa to the
target group (Table 1). Next, we highlighted "non-patho-
gen Bacteria" and moved those 52 taxa to the background
group. Finally, we selected a minimum of five hits to the
target and 3 hits to the background and the 50% identity
and 90% query coverage cutoffs. These search criteria
identified 1024 cluster profiles summarized in Table 2.
Experimental methods
Bacteria and plasmids used in this work are listed in addi-
tional file 4. Y. pseudotuberculosis strain IP32953 was
selected because the complete genome sequence is availa-
ble [45]. It was maintained in Luria-Bertani (LB) broth
and on LB agar. Plasmid pAJD434 [46] and PCR products
were introduced into Y. pseudotuberculosis IP32953 by elec-
troporation. PCR products were purified using Millipore
Microcon Ultracel YM-100. All Y. pseudotuberculosis
IP32953 strains containing the pAJD434 plasmid were
grown in LB media supplemented with 100 μg/ml tri-
methoprim, and 0.8% arabinose when λ Red Recombi-
nase genes were required to be induced at 28°C. Mutants
constructed in Y. pseudotuberculosis IP32953 were grown in
LB supplemented with kanamycin at a final concentration
of 50 μg/ml. Congo-red magnesium oxalate (CR-MOX)
agar were prepared as described by Riley and Toma [47].
Unless otherwise stated, chemicals were purchased from
Sigma-Aldrich (Poole, United Kingdom). Enzymes were
purchased from Promega Ltd (Southampton, United
Kingdom).
Construction of Y. pseudotuberculosis mutants was carried
out using a previously published method [48]. Briefly,
primers were designed for each target gene to be disrupted
that included 20 bp complementary to the 5' or 3'
sequence of the kanamycin gene of the plasmids pK2 or
pUC4K followed by 50 bp of upstream or downstream
sequence flanking the gene to be disrupted. PCR products
were generated using the plasmid pK2 as a template,
excess template was digested with DpnI and the PCR prod-
ucts were transformed into Y. pseudotuberculosis IP32953
pAJD434, by electroporation. Following overnight incu-
bation at 28°C in LB supplemented with 0.8% arabinose,
transformants were selected on LB agar supplemented
with kanamycin (50 μg/ml) and trimethoprim (100 μg/
ml) for 48 h at 28°C. Transformants were screened by
PCR using target gene-specific and kanamycin gene-spe-
cific primers (Additional file 5). Mutant strains were cured
of the pAJD434 plasmid by growth at 37°C in LB media
supplemented with kanamycin (50 μg/ml). Cured mutant
strains were screened for the virulence plasmid pYV by
PCR for two genes located on this plasmid; virF and yscC
(Additional file 6). The retention of the Yersinia virulence
plasmid (pYV) was also confirmed by culture on CR-MOX
plates, where plasmid retention results in small red colo-
nies and plasmid loss results in large pink colonies [47].
To measure bacterial growth, mutants and wild-type bac-
teria were grown overnight in 20 ml LB broth (wild type)
or 20 ml LB broth + kanamycin (50 μg/ml, mutants) with
shaking at 28°C. 100 ml of fresh culture of the same
medium were seeded from the over-night cultures and
grown at 28°C as before. Growth was recorded over 24
hours by measuring the OD600 at various time-points and
the growth curves were graphed and analysed using
Graphpad PRISM v4.0. Data was fit to the model: Y = Bot-
tom + (Top-Bottom)/(1+10^((LogEC50-X)*HillSlope)),
where X is the logarithm of time, Y is the response; Y startsBMC Genomics 2009, 10:501 http://www.biomedcentral.com/1471-2164/10/501
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at the Bottom and goes to the Top with a sigmoid shape.
Growth curves were compared using an ANCOVA (Analy-
sis of Covariance).
The median lethal dose (MLD), the expected median dose
required to produce morbidity or death in 50% of the
population tested, was determined as previously
described [49]. Briefly, groups of six female 6-week-old
BALB/c mice (Charles River laboratories) were infected via
intravenous (i.v.) injection with 0.1 ml serially diluted (in
sterile PBS) exponential-phase cultures grown at 28°C in
LB broth (wild type) or LB broth supplemented with kan-
amycin (mutant). Humane endpoints were strictly
observed, and animals deemed incapable of survival
(unable to right themselves or unresponsive to a pinch on
the foot or tail) were killed by cervical dislocation. The
MLD was calculated by the method of Reed and Muench
[50].
For in vivo competitive index studies, mutant and wild-
type strains were grown separately to exponential phase in
20 ml LB broth with shaking. Broth cultures were then
centrifuged (10 minutes, 4,000 g) and the pellet re-sus-
pended in 10 ml sterile PBS and centrifuged again (10
minutes, 4,000 g). The bacteria were washed and re-sus-
pended in 10 ml PBS and the optical density adjusted to
an OD600 of 0.55 to 0.6 with sterile PBS. Wild type and
mutant bacterial suspensions were then mixed in a 1:1
ratio and serially diluted with sterile PBS to give an inoc-
ulation concentration of approximately 1 × 103 cfu/ml.
Groups of 6 mice were then dosed with 0.1 ml of this solu-
tion by the i.v. route as above. Retrospective viable counts
were determined by plating out dilutions (in triplicate) on
LB agar and LB agar supplemented with kanamycin to
determine the input ratio. After 5 days, spleens were
recovered and passed through sieves (70 μm; Becton Dick-
inson) to produce a cell suspension in 3 ml of PBS. Cell
suspensions were serially diluted in sterile PBS and plated
onto LB agar and LB agar supplemented with kanamycin
to determine the output ratio. The competitive index (CI)
is defined as the output ratio (mutant/wild type) divided
by the input ratio (mutant/wild type) [51,52].
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